The prognostic value of estrogen receptor immunocytochemistry (ERICA) in breast cancer does not depend on the immunostaining intensity
Breast cancer; Estrogen receptor; Immunohistochemistry; Prognosis; Survival
Estrogen receptor status (ER) is traditionally determined by the immunocytochemical assay (ERICA) utilizing a formula, the HSCORE, based on the stain intensity and the percentage of ER-positive cells (%PC). The stain intensity is difficult to control and its determination is subjective. To determine whether %PC alone can be used instead of HSCORE in determining ER status in breast cancer, frozen samples from 65 breast cancers were assayed for ER by the dextran-coated charcoal assay (DCCA), HSCORE, and %PC. %PC and HSCORE correlated well. ER status determined by any of the three methods was a significant prognostic factor. When applied to paraffin sections of a different group of 91 cancers, ER %PC and DCCA did not give significant results. We conclude that (1) %PC may be used instead of HSCORE for determining ER in tissue sections and (2) inconsistencies of the prognostic significance of ER may be due to differences in populations studied.
Younes, M., Laucirica, R., Miller, C., & Brown, R. (1996). The prognostic value of estrogen receptor immunocytochemistry (ERICA) in breast cancer does not depend on the immunostaining intensity. Breast Disease, 9 (3). Retrieved from https://hsrc.himmelfarb.gwu.edu/smhs_path_facpubs/1079